| 1 |
33787860 | Antineoplastic and anti-inflammatory effects of bortezomib on systemic chronic active EBV infection. | 2021 Apr 13 |
2 |
| 2 |
34041472 | Bortezomib treatment for refractory nontuberculous mycobacterial infection in the setting of interferon gamma autoantibodies. | 2021 |
1 |
| 3 |
27923823 | Bortezomib Relieves Immune Tolerance in Nasopharyngeal Carcinoma via STAT1 Suppression and Indoleamine 2,3-Dioxygenase Downregulation. | 2017 Jan |
1 |
| 4 |
28052005 | Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8+T cell antitumor function. | 2017 Jan 31 |
1 |
| 5 |
25854569 | [Sodium butyrate down-regulates IFN-γ-induced indoleamine 2, 3 dioxygenase and promotes its acetylation and ubiquitination in CNE2 nasopharyngeal carcinoma cells]. | 2015 Apr |
1 |
| 6 |
26431276 | Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-κB crosstalk. | 2015 Oct 20 |
2 |
| 7 |
26494122 | Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity. | 2015 Dec 15 |
1 |
| 8 |
26546878 | Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy. | 2015 Dec |
1 |
| 9 |
24380732 | Protective role of bortezomib in steatotic liver ischemia/reperfusion injury through abrogation of MMP activation and YKL-40 expression. | 2014 Mar |
1 |
| 10 |
24418325 | Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines. | 2014 Jan 13 |
7 |
| 11 |
23613854 | Anti-CD70 immunocytokines for exploitation of interferon-γ-induced RIP1-dependent necrosis in renal cell carcinoma. | 2013 |
2 |
| 12 |
23657944 | NF-κB inhibition by bortezomib permits IFN-γ-activated RIP1 kinase-dependent necrosis in renal cell carcinoma. | 2013 Aug |
4 |
| 13 |
23953575 | The protection and therapy effects of bortezomib in murine acute graft-versus-host disease. | 2013 Jul-Aug |
1 |
| 14 |
21658766 | Depletion of alloreactive T-cells in vitro using the proteasome inhibitor bortezomib preserves the immune response against pathogens. | 2011 Oct |
1 |
| 15 |
21998209 | Acquired STAT4 deficiency as a consequence of cancer chemotherapy. | 2011 Dec 1 |
1 |
| 16 |
19508976 | Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population. | 2009 Jul |
1 |
| 17 |
20029331 | Bortezomib can suppress activation of rapamycin-resistant memory T cells without affecting regulatory T-cell viability in non-human primates. | 2009 Dec 27 |
1 |
| 18 |
18181098 | Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits. | 2008 Feb 1 |
1 |
| 19 |
18539902 | Differential effects of donor T-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation. | 2008 Aug 15 |
2 |
| 20 |
18989635 | Stromal cells in bone marrow play important roles in pro-inflammatory cytokine secretion causing fever following bortezomib administration in patients with multiple myeloma. | 2008 Nov |
1 |
| 21 |
16282346 | Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. | 2006 May 1 |
2 |